ICU Medical, Inc. (ICUI)

ICU Medical, Inc.'s stock has been impacted by several events in the past six months. The company reported a GAAP net loss for Q1 2024 but showed revenue growth in Q2 2024 and Q1 2025. Analyst sentiments are mixed, with a consensus rating of "Moderate Buy," but some have lowered their price targets. The share price experienced a decline, and there was insider buying activity from a director and the CEO.

ICU Medical, Inc. generally experiences broad-based and healthy demand for its products across all geographies. The increasing global focus on patient safety and the rising prevalence of chronic diseases contribute to a growing demand for infusion therapy products. The company's revenue growth has also been positively impacted by the resolution of national shortages for IV Solutions.

ICU Medical, Inc. specializes in developing, manufacturing, and selling medical devices and solutions for infusion therapy and critical care markets. Founded in 1993, the company focuses on enhancing patient safety, improving clinical outcomes, and simplifying medical procedures. Its major product categories include infusion therapy products, infusion systems, vital care applications, and pharmacy compounding systems.

ICU Medical, Inc. has a significant global presence with operations in North America, Europe, Asia-Pacific, Latin America, and other international markets, including manufacturing facilities, R&D centers, sales offices, and distribution channels. The company is primarily focused on the U.S. market, which accounts for over 63% of its sales.

ICU Medical's brand reputation faced a challenge with an FDA warning letter issued in 2025 concerning modifications to certain infusion pumps, potentially leading to reputational damage and impacting product sales. The available information primarily focuses on financial performance and analyst sentiment rather than broader public perception or other reputational events.

Institutional investors hold a significant portion of ICU Medical, Inc.'s stock, ranging from approximately 84.64% to 96.10%, with major holders including BlackRock, Inc., Vanguard Group Inc., and Janus Henderson Group Plc. Individual ownership accounts for a smaller percentage, around 1.24%. Company insiders own 1.50% of the stock, with recent buying activity from the CEO and a director.